Our news
NeoPhore's CEO Presents at Morgan Stanley 23rd Annual Global Healthcare Conference | September 2025
NeoPhore's CEO - Michael Shih - recently presented the NeoPhore story at the Morgan Stanley Global Healthcare Conference on Monday September 8th…
Neophore appoints Michael Shih as Chief Executive Officer
NeoPhore appoints Michael Shih as Chief Executive Officer • Highly experienced corporate development leader with a track record of international p…
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore…
NeoPhore presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.
The NeoPhore team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024. In collaboration with The…
Other news
BioCentury's Emerging Company Profile
CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…
‘Big place’ for small-molecule booster drugs in cancer immunotherapy, says NeoPhore CEO
APM Health: Interview with CEO, Jeff Roix
NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology
Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…